Learning from clinical trials of neoadjuvant checkpoint blockade
Open accessThe DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Abstract
Neoadjuvant checkpoint inhibition, in which the therapy is administered before surgery, is a promising new approach to managing bulky but resectable melanoma, and is also being explored in other cancers. This strategy has a high pathologic response rate, which correlates with survival outcomes. The fact that biopsies are routinely available provides a unique opportunity for understanding the responses to therapy and carrying out reverse translation in which these data are used to select therapies in the clinic or in trials that are more likely to improve patient outcomes. In this Perspective, we discuss the rationale for neoadjuvant immunotherapy in resectable solid tumors based on preclinical and human translational data, summarize the results of recent clinical trials and ongoing research, and focus on future directions for enhancing reverse translation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Accumulating translational evidence supports the view that neoadjuvant ICI therapy might lead to increased immune cell activation mediated by the presence of the primary tumour in situ, including expansion of the T-cell clone pool and the immune reconstitution of exhausted tumour-specific lymphocytes.14”
From Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis (2024) · cites this paper as [14]
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationCancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationOverall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Self-citationNeoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Cited by
Ganesh, K., & Massagué, J. (2021) · Nature Medicine · doi:10.1038/s41591-020-01195-4 · Cited by 1,051
The foundations of immune checkpoint blockade and the ipilimumab approval decennial
Korman, A. J., Garrett-Thomson, S. C., & Lonberg, N. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00345-8 · Cited by 548
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
Blank, C. U., Lucas, M. W., Scolyer, R. A., van de Wiel, B. A., Menzies, A. M., Lopez-Yurda, M., Hoeijmakers, L. L., Saw, R. P. M., Lijnsvelt, J. M., Maher, N. G., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2402604 · Cited by 542
Self-citationLuoma, A. M., Suo, S., Wang, Y., Gunasti, L., Porter, C. B. M., Nabilsi, N., Tadros, J., Ferretti, A. P., Liao, S., Gurer, C., et al. (2022) · Cell · doi:10.1016/j.cell.2022.06.018 · Cited by 385
Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells
Baharom, F., Ramirez-Valdez, R. A., Tobin, K. K. S., Yamane, H., Dutertre, C.-A., Khalilnezhad, A., Reynoso, G. V., Coble, V. L., Lynn, G. M., Mulè, M. P., et al. (2021) · Nature Immunology · doi:10.1038/s41590-020-00810-3 · Cited by 202
Metadata
- Authors
- Versluis, J. M., Long, G. V., & Blank, C. U.
- Affiliations
- The Netherlands Cancer Institute (NL)
- The University of Sydney (AU)
- Corresponding author
- Blank, Christian U.
- Venue
- Nature Medicine
- Published
- 2020-04
- Volume
- 26
- Issue
- 4
- Pages
- 475-484
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W3015451486
- Cited by
- 234
- References
- 102
- Citations by year
- 2026: 29 · 2025: 49 · 2024: 48 · 2023: 41 · 2022: 33 · 2021: 23 · 2020: 11
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion, cc-by)
- Funders
- National Health and Medical Research Council
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- neoadjuvant immunotherapy, immune checkpoint inhibitors, melanoma, pathological response, reverse translation, translational oncology, antitumor immunity, clinical trial design
- MeSH terms
- Antineoplastic Agents, Immunological, Clinical Trials as Topic, Humans, Immunotherapy, Neoplasms, Neoadjuvant Therapy, Protein Kinase Inhibitors, Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Learning from clinical trials of neoadjuvant checkpoint blockade. https://app.cochat.ai/papers/10.1038/s41591-020-0829-0
- The paper
- Versluis, J. M., Long, G. V., & Blank, C. U. (2020). Learning from clinical trials of neoadjuvant checkpoint blockade. Nature Medicine. https://doi.org/10.1038/s41591-020-0829-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.